Retratrutide 30 mg

Retatrutide is an once-weekly "triple G" agonist (and Glucagon receptors) developed by Eli Lilly that has demonstrated significant weight loss (up to ~24% over 48 weeks) and improved metabolic markers. It is considered a potential next-generation obesity treatment that may surpass current medications in efficacy Mechanism of Action: By targeting three hormone receptors instead of one (like semaglutide) or two (like tirzepatide), it increases energy expenditure alongside appetite reduction. Research indicates substantial weight reductions, with some participants losing up to 24.2% of body weight after 48 weeks. have shown consistent weight loss and significant reductions in HbA1c in patients with type 2 diabetes. Targeted Conditions: In addition to obesity and type 2 diabetes, studies are exploring its impact on fatty liver disease (MASLD), knee osteoarthritis, and sleep apnea. Retatrutide is often called a "triple agonist" because it acts on the GLP-1, GIP, and glucagon receptors, providing a unique therapeutic approach to metabolic disease.